Cell signaling and cancer: a mechanistic insight into drug resistance

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · see citing works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

Integrin signaling

Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works

TGFβ signalling in context

Massagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,130 · see citing works

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,820 · see citing works

Drug resistance in cancer: An overview

Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463 · see citing works

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · see citing works

Role of integrins in cell invasion and migration

Hood, J. D., & Cheresh, D. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc727 · Cited by 1,781 · see citing works

Molecular mechanisms of drug resistance

Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,686 · see citing works

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,512 · see citing works

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,489 · see citing works

New and emerging HDAC inhibitors for cancer treatment

West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · see citing works

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works

Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer

Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199 · see citing works

Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors

Krishnamurthy, N., & Kurzrock, R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.002 · Cited by 1,026 · see citing works

Targeting the EGFR signaling pathway in cancer therapy

Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 920 · see citing works

Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance

Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915 · see citing works

Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines

Damiano, J. S., Cress, A. E., Hazlehurst, L., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 899 · see citing works

TGF-β signaling and epithelial–mesenchymal transition in cancer progression

Katsuno, Y., Lamouille, S., & Derynck, R. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b6371 · Cited by 785 · see citing works

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo

Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D. M., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R. M., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739 · see citing works

The role of TGF-β/SMAD4 signaling in cancer

Zhao, M., Mishra, L., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23230 · Cited by 631 · see citing works

Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells

Zheng, P., Chen, L., Yuan, X., Luo, Q., Liu, Y., Xie, G., Ma, Y., & Shen, L. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0528-y · Cited by 630 · see citing works

Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

Wang, Z. P., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., Ali, S. S., Abbruzzese, J. L., Gallick, G. E., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4312 · Cited by 620 · see citing works

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588 · see citing works

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557 · see citing works

Regulation of EMT by TGFβ in cancer

Heldin, C., Vanlandewijck, M., & Moustakas, A. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.037 · Cited by 502 · see citing works

Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter

Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486 · see citing works

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471 · see citing works

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430 · see citing works

Targeting Notch signaling pathway in cancer: Clinical development advances and challenges

Takebe, N., Nguyen, D., & Yang, S. X. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.005 · Cited by 416 · see citing works

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

Yang, C., Li, Z., Bhatt, T., Dickler, M. N., Giri, D. D., Scaltriti, M., Baselga, J. M., Rosen, N. X., & Chandarlapaty, S. (2016) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 413 · see citing works

Epigenetic Resensitization to Platinum in Ovarian Cancer

Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390 · see citing works

TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389 · see citing works

Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer

Rodilla, V., Villanueva, A., Obrador‐Hevia, A., Robert‐Moreno, A., Fernández‐Majada, V., Grilli, A., López-Bigas, N., Bellora, N., Albà, M. M., Torres, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813221106 · Cited by 384 · see citing works

BET Bromodomain Inhibition of MYC -Amplified Medulloblastoma

Bandopadhayay, P., Bergthold, G., Nguyen, B., Schubert, S., Gholamin, S., Tang, Y., Bolin, S., Schumacher, S. E., Zeid, R., Masoud, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2281 · Cited by 356 · see citing works

Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells

Sherman‐Baust, C. A., Weeraratna, A. T., Rangel, L. B. A., Pizer, E. S., Cho, K. R., Schwartz, D. R., Shock, T. L., & Morin, P. J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00058-8 · Cited by 340 · see citing works

Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells

Aoudjit, F., & Vuori, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204554 · Cited by 325 · see citing works

Type I Collagen Promotes the Malignant Phenotype of Pancreatic Ductal Adenocarcinoma

Armstrong, T., Packham, G., Murphy, L. B., Bateman, A. C., Conti, J. A., Fine, D. R., Johnson, C., Benyon, R. C., & Iredale, J. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0825 · Cited by 317 · see citing works

Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment

Vilchez, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.823 · Cited by 312 · see citing works

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

Cheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L. A., Thompson, R. C., Müller, S., Knapp, S., & Wang, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3066 · Cited by 302 · see citing works

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Wang, Y., Bernhardy, A. J., Cruz, C., Krais, J. J., Nacson, J., Nicolas, É., Peri, S., van der Gulden, H. M. L., van der Heijden, I., O’Brien, S. W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0186 · Cited by 271 · see citing works

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Yu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2961 · Cited by 259 · see citing works

A Convergence-Based Framework for Cancer Drug Resistance

Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258 · see citing works

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells

Calabretta, S., Bielli, P., Passacantilli, I., Pilozzi, E., Fendrich, V., Capurso, G., Fave, G. D., & Sette, C. (2015) · Oncogene · doi:10.1038/onc.2015.270 · Cited by 252 · see citing works

Targeting Notch signaling pathway to overcome drug resistance for cancer therapy

Wang, Z. P., Li, Y., Ahmad, A., Azmi, A. S., Banerjee, S., Kong, D., & Sarkar, F. H. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.06.001 · Cited by 233 · see citing works

Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance

Wickström, M., Dyberg, C. H., Milosevic, J., Einvik, C., Calero, R., Sveinbjørnsson, B., Sandén, E., Darabi, A., Siesjö, P., Kool, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9904 · Cited by 229 · see citing works

Mitogenic Signal Transduction by Integrin- and Growth Factor Receptor-mediated Pathways

Lee, S. E., & Juliano, R. L. (2004) · Molecules and Cells · doi:10.1016/s1016-8478(23)13026-3 · Cited by 213 · see citing works

Drug resistance to targeted therapies: Déjà vu all over again

Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 211 · see citing works

Integrin Signaling in Cancer Cell Survival and Chemoresistance

Aoudjit, F., & Vuori, K. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/283181 · Cited by 207 · see citing works

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

Dardaei, L., Wang, H. Q., Singh, M., Fordjour, P., Shaw, K. X., Yoda, S., Kerr, G., Yu, K., Liang, J., Cao, Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4497 · Cited by 199 · see citing works

Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance

Nagaraj, A. B., Joseph, P. L., Kovalenko, O., Singh, S., Armstrong, A. J., Redline, R. W., Resnick, K. E., Zanotti, K. M., Waggoner, S. E., & DiFeo, A. V. (2015) · Oncotarget · doi:10.18632/oncotarget.4690 · Cited by 196 · see citing works

Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy

Wang, B., Tian, T., Kalland, K., Ke, X., & Qu, Y. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.008 · Cited by 193 · see citing works

Systematic identification of signaling pathways with potential to confer anticancer drug resistance

Martz, C. A., Ottina, K. A., Singleton, K. R., Jasper, J. S., Wardell, S. E., Peraza-Penton, A., Anderson, G. R., Winter, P. S., Wang, T., Alley, H. M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.aaa1877 · Cited by 191 · see citing works

Activation of notch‐1 enhances epithelial–mesenchymal transition in gefitinib‐acquired resistant lung cancer cells

Xie, M., Zhang, L., He, C., Xu, F., Liu, J., Hu, Z., Zhao, L., & Tian, Y. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24019 · Cited by 191 · see citing works

A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis

Vecchione, A. M., Belletti, B., Lovat, F., Volinia, S., Chiappetta, G., Giglio, S., Sonego, M., Cirombella, R., Onesti, C. E., Pellegrini, P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305472110 · Cited by 188 · see citing works

The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Kim, Y.-W., Ko, J., Cui, Z.-Y., Abolhoda, A., Ahn, J. S., Ou, S.-H., Ahn, M., & Park, K. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0750 · Cited by 179 · see citing works

TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis

Xu, X., Zhang, L., He, X., Zhang, P., Sun, C., Xu, X., Lu, Y., & Li, F. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.139 · Cited by 176 · see citing works

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D. T., Hu, Y., Zhong, W., Randell, S., Sadek, N. L., et al. (2017) · Nature · doi:10.1038/nature24040 · Cited by 168 · see citing works

Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy

Leary, M., Heerboth, S., LAPINSKA, K., & Sarkar, S. (2018) · Cancers · doi:10.3390/cancers10120483 · Cited by 166 · see citing works

Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death.

Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J., & Gladson, C. L. (1999) · PubMed · Cited by 165 · see citing works

Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines

Wu, H., Zhiyong, L., Xiaohua, S., Xinyu, R., Wang, K., & Tonghua, L. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-125 · Cited by 157 · see citing works

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK

Martinelli, E., Morgillo, F., Troiani, T., & Ciardiello, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.001 · Cited by 156 · see citing works

Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer

Zhang, Z., Cheng, L., Li, J., Farah, E., Atallah, N. M., Pascuzzi, P. E., Gupta, S., & Liu, X. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3006 · Cited by 152 · see citing works

MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway

Miao, Y., Zheng, W., Li, N., Su, Z., Zhao, L., Zhou, H., & Li, J. (2017) · Scientific Reports · doi:10.1038/srep41942 · Cited by 150 · see citing works

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)

Oliveras‐Ferraros, C., Corominas-Faja, B., Cufí, S., Vázquez‐Martín, A., Martı́n-Castillo, B., Iglesias, J. M., López‐Bonet, E., Martín, Á. G., & Menéndez, J. A. (2012) · Cell Cycle · doi:10.4161/cc.22225 · Cited by 146 · see citing works

Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells.

Chikazawa, N., Tanaka, H., Tasaka, T., Nakamura, M., Tanaka, M., Onishi, H., & Katano, M. (2010) · PubMed · Cited by 145 · see citing works

Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling

Emons, G., Spitzner, M., Reineke, S., Möller, J., Auslander, N., Krämer, F., Hu, Y., Beißbarth, T., Wolff, H. A., Rave‐Fränk, M., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0205 · Cited by 144 · see citing works

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles

Martínez, V. G., O’Neill, S., Salimu, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1362530 · Cited by 138 · see citing works

ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase

Hodkinson, P. S., Elliott, T., Wong, W. S., Rintoul, R. C., MacKinnon, A. C., Haslett, C., & Sethi, T. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401849 · Cited by 136 · see citing works

Disruption of Laminin-Integrin-CD151-Focal Adhesion Kinase Axis Sensitizes Breast Cancer Cells to ErbB2 Antagonists

Yang, X. H., Flores, L. M., Li, Q., Zhou, P., Xu, F., Krop, I. E., & Hemler, M. E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4032 · Cited by 134 · see citing works

TGF-β: An emerging player in drug resistance

Brunen, D., Willems, S., Kellner, U., Midgley, R., Simon, I., & Bernards, R. (2013) · Cell Cycle · doi:10.4161/cc.26034 · Cited by 124 · see citing works

Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells

Samuel, P., Mulcahy, L. A., Furlong, F. M., McCarthy, H. O., Brooks, S. A., Fabbri, M., Pink, R. C., & Carter, D. R. F. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0065 · Cited by 124 · see citing works

The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule‐Targeting Drugs in Prostate Cancer

Liu, Z., Zhu, G., Getzenberg, R. H., & Veltri, R. W. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25091 · Cited by 116 · see citing works

Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters

Fan, Y.-F., Zhang, W., Zeng, L., Lei, Z.-N., Cai, C.-Y., Gupta, P., Yang, D.-H., Cui, Q., Qin, Z.-D., Chen, Z.-S., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.021 · Cited by 116 · see citing works

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

Zhou, H., Kim, Y.-S., Peletier, A., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.046 · Cited by 115 · see citing works

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

Guerrab, A. E., Bamdad, M., Kwiatkowski, F., Bignon, Y., Penault-Llorca, F. M., & Aubel, C. (2016) · Oncotarget · doi:10.18632/oncotarget.12037 · Cited by 115 · see citing works

Notch1 regulates the expression of the multidrug resistance gene ABCC1 / MRP1 in cultured cancer cells

Cho, S., Lü, M., He, X., Ee, P. L. R., Bhat, U. G., Schneider, E., Miele, L., & Beck, W. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019452108 · Cited by 113 · see citing works

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Drilon, A. E. D. C., Fu, S., Patel, M. R., Fakih, M., Wang, D., Olszanski, A. J., Morgensztern, D., Liu, S. V., Cho, B. C., Bazhenova, L. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0839 · Cited by 112 · see citing works

EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function

Phuchareon, J., McCormick, F. P., Eisele, D. W., & Tetsu, O. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510733112 · Cited by 105 · see citing works

BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells

Das, C. K., Linder, B., Bonn, F., Rothweiler, F., Đikić, I., Michaelis, M., Cinatl, J. J., Mandal, M., & Kögel, D. (2018) · Neoplasia · doi:10.1016/j.neo.2018.01.001 · Cited by 105 · see citing works

TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3

Hesler, R., Huang, J. J., Starr, M. D., Treboschi, V. M., Bernanke, A., Nixon, A. B., McCall, S. J., White, R. R., & Blobe, G. C. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw093 · Cited by 104 · see citing works

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway

Chen, D., Lin, X., Zhang, C., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0132-2 · Cited by 103 · see citing works

Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks

Chakraborty, S., Li, L., Puliyappadamba, V. T., Guo, G., Hatanpaa, K. J., Mickey, B., Souza, R. F., Vo, P., Herz, J., Chen, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6811 · Cited by 99 · see citing works

ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling

Vesel, M., Rapp, J., Feller, D., Kiss, E., Járomi, L., Meggyes, M., Miskei, G., Duga, B., Smuk, G., László, T., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0537-6 · Cited by 97 · see citing works

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94 · see citing works

Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma

Uramoto, H., Shimokawa, H., Hanagiri, T., Kuwano, M., & Ono, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.008 · Cited by 83 · see citing works

Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines

Januchowski, R., Sterzyńska, K., Zaorska, K., Sosińska, P., Klejewski, A., Brązert, M., Nowicki, M. O., & Zabel, M. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0278-z · Cited by 83 · see citing works

Activation of RAS family members confers resistance to ROS1 targeting drugs

Cargnelutti, M., Corso, S., Pergolizzi, M., Mévellec, L., Aisner, D. L., Dziadziuszko, R., Varella‐Garcia, M., Comoglio, P. M., Doebele, R. C., Vialard, J. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3311 · Cited by 80 · see citing works

Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer

De Robertis, M., Loiacono, L., Fusilli, C., Poeta, M. L., Mazza, T., Sanchez, M., Marchionni, L., Signori, E., Lamorte, G., Vescovi, A. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0709 · Cited by 78 · see citing works

TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2

Tan, Z., Song, L., Wu, W., Zhou, Y., Zhu, J., Wu, G., Cao, L., Song, J., Li, J., & Zhang, W. (2018) · Oncogene · doi:10.1038/s41388-018-0344-7 · Cited by 78 · see citing works

Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy

Wu, D., Wang, D. C., Cheng, Y., Qian, M., Zhang, M., Shen, Q., & Wang, X. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.006 · Cited by 76 · see citing works

Integrin beta1 over‐expression associates with resistance to tyrosine kinase inhibitor gefitinib in non‐small cell lung cancer

Ju, L., Zhou, C., Li, W., & Yan, L. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22888 · Cited by 75 · see citing works

RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer

Ji (2010) · Oncology Reports · doi:10.3892/or_00000712 · Cited by 74 · see citing works

GOLM1 promotes prostate cancer progression through activating PI3K‐AKT‐mTOR signaling

Yan, G., Ru, Y., Wu, K., Yan, F., Wang, Q., Wang, J., Pan, T., Zhang, M., Han, H., Li, X., et al. (2017) · The Prostate · doi:10.1002/pros.23461 · Cited by 73 · see citing works

A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF V600E-Mutant Brain Tumor

Wang, J., Yao, Z., Jonsson, P., Allen, A. N., Qin, A. C. R., Uddin, S., Dunkel, I. J., Petriccione, M., Manova, K., Haque, S. S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1263 · Cited by 68 · see citing works

L1CAM–integrin interaction induces constitutive NF-κB activation in pancreatic adenocarcinoma cells by enhancing IL-1β expression

Kiefel, H., Bondong, S., Erbe-Hoffmann, N., et al. (2010) · Oncogene · doi:10.1038/onc.2010.230 · Cited by 66 · see citing works

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines

Zhang, W., Peyton, M., Xie, Y., Soh, J., Minna, J. D., Gazdar, A. F., & Frenkel, E. P. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318194fae7 · Cited by 66 · see citing works

MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer

Xie, M., Fu, Z., Cao, J., Liu, Y., Wu, J., Li, Q., & Chen, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.088 · Cited by 66 · see citing works

Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain®in human tumour and normal cellsin vitro

Cordes, N., Bläse, M., Plaßwilm, L., Rodemann, H. P., & Beuningen, D. V. (2003) · International Journal of Radiation Biology · doi:10.1080/09553000310001610240 · Cited by 65 · see citing works

MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK ‐mediated HER 2 phosphorylation at Thr701

Chen, C., Hsia, T., Yeh, M., Chen, T.-H., Chen, Y., Chen, J., Wei, Y., Tu, C., & Huang, W. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12102 · Cited by 65 · see citing works

Matrine reversed multidrug resistance of breast cancer MCF‐7/ADR cells through PI3K/AKT signaling pathway

Zhou, B., Wei, C., Zhang, S., et al. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26502 · Cited by 64 · see citing works

Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma

Hong, S., Kao, Y.-R., Lee, T., & Wu, C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3858 · Cited by 63 · see citing works

Epithelial–Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines

Zhao, H., Desai, V., Wang, J., Epstein, D. M., Miglarese, M. R., & Buck, E. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0327 · Cited by 61 · see citing works

Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitro

Suwala, A. K., Koch, K., Herrera-Rios, D., Aretz, P., Uhlmann, C., Ogorek, I., Felsberg, J., Reifenberger, G., Köhrer, K., Deenen, R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25210 · Cited by 60 · see citing works

RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1 -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade

Bockorny, B., Rusan, M., Chen, W., Liao, R. G., Li, Y. Y., Piccioni, F., Wang, J., Tan, L., Thorner, A. R., Li, T., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0464 · Cited by 59 · see citing works

Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors

Lai, F., Jin, L., Gallagher, S. J., Mijatov, B., Zhang, X. D., & Hersey, P. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00002-6 · Cited by 55 · see citing works

Mechanisms of Primary Drug Resistance in FGFR1 -Amplified Lung Cancer

Malchers, F., Ercanoglu, M. S., Schütte, D., Castiglione, R., Tischler, V., Michels, S. Y. F., Dahmen, I., Brägelmann, J., Menon, R., Heuckmann, J. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0478 · Cited by 53 · see citing works

Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas

Folgiero, V., Avetrani, P., Bon, G., Carlo, S. E. D., Fabi, A., Nisticò, C., Vici, P., Melucci, E., Buglioni, S., Perracchio, L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001592 · Cited by 51 · see citing works

The structural basis for cancer treatment decisions

Nussinov, R., Jang, H., & Tsai, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2439 · Cited by 51 · see citing works

Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo

Su, Y., Li, X., Ma, J., Zhao, J., Liu, S., Wang, G., Edwards, H. J., Taub, J. W., Lin, H., & Ge, Y. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.11.022 · Cited by 50 · see citing works

Microenvironmental Signals and Biochemical Information Processing: Cooperative Determinants of Intratumoral Plasticity and Heterogeneity

Davies, A. E., & Albeck, J. G. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00044 · Cited by 50 · see citing works

G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance

Blake, A., Dragan, M., Tirona, R. G., Hardy, D. B., Brackstone, M., Tuck, A. B., Babwah, A. V., & Bhattacharya, M. M. (2017) · Scientific Reports · doi:10.1038/srep46525 · Cited by 48 · see citing works

Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion

Vijayaraghavalu, S., & Labhasetwar, V. D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.12.009 · Cited by 47 · see citing works

Parathyroid Hormone-Related Protein Regulates Cell Survival Pathways via Integrin α6β4-Mediated Activation of Phosphatidylinositol 3-Kinase/Akt Signaling

Bhatia, V., Mula, R. V. R., Weigel, N. L., & Falzon, M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0568 · Cited by 47 · see citing works

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Ninomiya, K., Ohashi, K., Makimoto, G., Tomida, S., Higo, H., Kayatani, H., Ninomiya, T., Kubo, T., Ichihara, E., Hotta, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20326-z · Cited by 45 · see citing works

Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells

Pearce, M. C., Gamble, J. T., Kopparapu, P., O’Donnell, E. F., Mueller, M., Jang, H. S., Greenwood, J. A., Satterthwait, A. C., Tanguay, R. L., Zhang, X.-K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25437 · Cited by 44 · see citing works

Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: Involvement of the insulin like growth factor‐1 receptor

Thomas, F., Holly, J. M. P., Persad, R. A., Bahl, A. K., & Perks, C. M. (2010) · The Prostate · doi:10.1002/pros.21119 · Cited by 39 · see citing works

Mechanisms of Resistance to RAF Inhibition in Melanomas Harboring a BRAF Mutation

Chapman, P. B. (2013) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2013.33.e80 · Cited by 38 · see citing works

Src-Induced Cisplatin Resistance Mediated by Cell-to-Cell Communication

Peterson-Roth, E., Brdlik, C. M., & Glazer, P. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0985 · Cited by 37 · see citing works

Cross-Talk Between Notch and EGFR Signaling in Human Breast Cancer Cells

Dai, J., Ma, D., Zang, S., et al. (2009) · Cancer Investigation · doi:10.1080/07357900802563036 · Cited by 37 · see citing works

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer

Lombard, A. P., Liu, L., Cucchiara, V., Liu, C., Armstrong, C. M., Zhao, R., Yang, J. C., Lou, W., Evans, C. P., & Gao, A. C. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1269 · Cited by 36 · see citing works

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments

Wang, D. D., Ma, L., Wong, M. P., Lee, V. H.-F., & Yan, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128360 · Cited by 35 · see citing works

Melanoma Mutagenesis and Aberrant Cell Signaling

Bello, D. M., Ariyan, C. E., & Carvajal, R. D. (2013) · Cancer Control · doi:10.1177/107327481302000404 · Cited by 34 · see citing works

Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells

Muguruma, Y., Yahata, T., Warita, T., et al. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0001-3 · Cited by 34 · see citing works

Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition

Zoppoli, G. M., Moran, E., Soncini, D., et al. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054211 · Cited by 33 · see citing works

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

Baldacci, S., Mazières, J., Tomasini, P., Girard, N., Guisier, F., Audigier-Valette, C., Monnet, I., Wislez, M., Pérol, M., Dô, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21707 · Cited by 32 · see citing works

Chemotherapy Research and Practice

(2010) · Chemotherapy Research and Practice · doi:10.1155/chrp · Cited by 32 · see citing works

Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones

Hiroshi Yoneyama, C., Takizawa-Hashimoto, A., Takeuchi, O., et al. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000165 · Cited by 31 · see citing works

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition

Zapater, E. O., Lee, R. W., Owen, W. J., Weitsman, G. E., Fruhwirth, G. O., Dunn, R. G., Neat, M. J., McCaughan, F. M., Parker, P. J., Ng, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170798 · Cited by 30 · see citing works

Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins

Wang, J., Chen, Y., Xiang, F., et al. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1374285 · Cited by 30 · see citing works

Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt/β-catenin signaling

Zhang, K., Li, M., Huang, H., Li, L., Yang, J., Feng, L., Gou, J., Jiang, M., Peng, L., Chen, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23253 · Cited by 30 · see citing works

Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis

Pu, H., Begemann, D. E., & Kyprianou, N. (2017) · Endocrinology · doi:10.1210/en.2017-00086 · Cited by 28 · see citing works

RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition

Earwaker, P., Anderson, C. J., Willenbrock, F. W., Harris, A. L., Protheroe, A. S., & Macaulay, V. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191890 · Cited by 28 · see citing works

Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine

Hosokawa, M., Mai, S., NAKANO, A., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.3253 · Cited by 27 · see citing works

Hedyotis�diffusa Willd inhibits proliferation and induces apoptosis of 5‑FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway

Li, Q., Lai, Z., Yan, Z., Peng, J., Jin, Y., Wei, L., & Lin, J. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7903 · Cited by 27 · see citing works

MYCN is a novel oncogenic target in adult B‐ ALL that activates the Wnt/β‐catenin pathway by suppressing DKK 3

Kong, D., Zhao, L., Sun, L., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13644 · Cited by 24 · see citing works

K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines

Yeung, Y. H., Lau, D. K., Chionh, F. J. M., Tran, H., Tse, J. W. T., Weickhardt, A. J., Nikfarjam, M., Scott, A. M., Tebbutt, N. C., & Mariadason, J. M. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12078 · Cited by 23 · see citing works

Overexpression of Human ABCB1 in Cancer Cells Leads to Reduced Activity of GSK461364, a Specific Inhibitor of Polo-like Kinase 1

Wu, C., Hsiao, S.-H., Luo, S.-Y., Tuo, W.-C., Su, C.-Y., Li, Y., Huang, Y.-H., & Hsieh, C. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500492r · Cited by 22 · see citing works

Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells

Bertacchini, J., Frasson, C., Chiarini, F., D'Avella, D., Accordi, B., Anselmi, L., Barozzi, P., Forghieri, F., Luppi, M., Martelli, A. M., et al. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.03.001 · Cited by 22 · see citing works

Mechanisms of Resistance to RAF Inhibition in Melanomas Harboring a BRAF Mutation

Chapman, P. B. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.80 · Cited by 20 · see citing works

Different gap junction-propagated effects on cisplatin transfer result in opposite responses to cisplatin in normal cells versus tumor cells

Zhang, Y., Tao, L., Fan, L., et al. (2015) · Scientific Reports · doi:10.1038/srep12563 · Cited by 18 · see citing works

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance

Fischer, T., Najjar, A., Totzke, F., et al. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1370583 · Cited by 17 · see citing works

Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial–mesenchymal transition phenotype

Xu, J., Zhao, X., He, D., Wang, J., Li, W., Liu, Y., Ma, L., Jiang, M., Yu, T., Wang, Z., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2668-7 · Cited by 16 · see citing works

Collagen type I signaling reduces the expression and the function of human receptor activator of nuclear factor ‐κB ligand (RANKL) in T lymphocytes

Gendron, S., Couture, J., & Aoudjit, F. (2005) · European Journal of Immunology · doi:10.1002/eji.200535065 · Cited by 14 · see citing works

Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis

Wang, Y., Yuan, W., Ma, X., et al. (2018) · Medicine · doi:10.1097/md.0000000000011346 · Cited by 14 · see citing works

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

(2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7 · Cited by 11 · see citing works

Correction: TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2

Tan, Z., Song, L., Wu, W., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0467-x · Cited by 8 · see citing works

Dysregulation and detection methods of EGFR in oral cancer. A narrative review.

Chile., F. D. O. U. A. B., Somarriva, C., Fernández, A., V, et al. (2016) · Journal Of Oral Research · doi:10.17126/joralres.2016.057 · Cited by 3 · see citing works

SHP2 Inhibition Abrogates MEK inhibitor Resistance in Multiple Cancer ModelsPreprint

Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Araki, K. Y., Simeone, D. M., Miller, G., Neel, B. G., & Tang, K. H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/307876 · Cited by 3 · see citing works

Abstract PD4-08: A microenvironment secretome screen reveals FGF2 as a mediator of resistance to anti-estrogens and PI3K/mTOR pathway inhibitors in ER+ breast cancer

Shee, K., Hinds, J., Yang, W., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd4-08 · Cited by 2 · see citing works

MP70-11 REVERSE OF DOCETAXEL RESISTANCE IN PROSTATE CANCER VIA NOTCH SIGNALING INHIBITION

Shi, Q., Tu, X., Wei, Q., et al. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.02.2255 · Cited by 1 · see citing works

A novel synthetic compound overcomes drug resistance on EGFR (T790M) and cancer stemness in human non‐small cell lung cancer

Pan, P., Chang, C., Liu, K., Chan, Y., Chen, Y., & Chao, J. (2017) · The FASEB Journal · doi:10.1096/fasebj.31.1_supplement.lb181 · Cited by 1 · see citing works

Editorial Comment

Matin, S. F. (2018) · The Journal of Urology · doi:10.1016/j.juro.2017.10.064 · Cited by 1 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Differential WNT gene expression in various subtypes of acute lymphoblastic leukemia.

Memarian, A., Parvaneh, V., Asgarian‐Omran, H., et al. (2012) · PubMed · doi:10.22034/iji.2012.16858 · Cited by 5 · see citing works

Wnt Versus Wnt

(2003) · Science s STKE · doi:10.1126/stke.2003.200.tw361

943 Temporal-spatial activation of Wnt-signaling within Type1 / Type 2 immunity during wound healing

Ferrer, R. A., Ordieres, M. D., Simon, J. C., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.03.1019

The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application

Grebennikova, T. A., Belaya, Z. E., Rozhinskaya, L. Y., & Mel'nichenko, G. A. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh201688674-81 · Cited by 24 · see citing works

Advancement of Wnt signal pathway and the target of breast cancer

Liang, Q., Li, W., Zhao, Z., & Fu, Q. (2016) · Open Life Sciences · doi:10.1515/biol-2016-0013 · Cited by 5 · see citing works